Defense counsel in the Zoloft multidistrict litigation argued in federal court Wednesday that scientific and medical issues should take primacy in pretrial proceedings because as one lawyer said, “there’s just no science there.”
But plaintiffs counsel argued that discovery can proceed on multi-tracks for both Pfizer’s alleged liability and for the science behind the allegations that women’s use of the popular antidepressant during their pregnancies caused birth defects in their children.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
